ADC Therapeutics SA
ADCT- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001771910
No open-market purchases or sales by ADC Therapeutics SA insiders were filed in the last 90 days; 113 institutions reported holding it in 13F filings for Q2 2026, worth $86.3M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding ADC Therapeutics SA changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 55 | 49 | −6 |
| Shares | 33.8M | 34.1M | +324.7K (+1.0%) |
| Value | $682.8M | $501.3M | −$181.5M (−26.6%) |
New holders (4)
Institutions that held ADC Therapeutics SA at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Matrix Capital Management Company, LP | 400,000 | $5.88M | 0.07% |
| Manufacturers Life Insurance Company, The | 64,402 | $951.9K | 0.00% |
| Prospera Financial Services Inc | 5,921 | $87.0K | 0.00% |
| Assetmark, Inc | 165 | $2.00K | 0.00% |
Sold out (10)
Institutions that held ADC Therapeutics SA at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Invesco Ltd. | 242,643 | $4.90M |
| Millennium Management LLC | 40,367 | $815.0K |
| Susquehanna International Group, LLP | 25,866 | $522.0K |
| Caas Capital Management LP | 12,958 | $262.0K |
| UBS Group AG | 2,426 | $49.0K |
| Lazard Asset Management LLC | 1,863 | $37.0K |
| Dark Forest Capital Management LP | 387 | $8.00K |
| Group One Trading, L.P. | 100 | $2.00K |
| Toth Financial Advisory Corp | 70 | $1.00K |
| Simplex Trading, LLC | 89 | $1.00K |